(Q45955692)

18 December 2017

title

Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease. (English)

1 reference

18 December 2017

1 reference

Maike Anna Michaels

1

1 reference

18 December 2017

Sebastian Torben Jendrek

2

1 reference

18 December 2017

Tobias Korf

3

1 reference

18 December 2017

Thomas Nitzsche

4

1 reference

18 December 2017

Bianca Teegen

5

1 reference

18 December 2017

Lars Komorowski

6

1 reference

18 December 2017

Stefanie Derer

7

1 reference

18 December 2017

Torsten Schröder

8

1 reference

18 December 2017

Florian Baer

9

1 reference

18 December 2017

Henrik Lehnert

10

1 reference

18 December 2017

Jürgen Büning

11

1 reference

18 December 2017

Klaus Fellerman

12

1 reference

18 December 2017

Christian Sina

13

1 reference

18 December 2017

publication date

13 August 2015

1 reference

18 December 2017

Inflammatory Bowel Diseases

published in

1 reference

18 December 2017

volume

21

1 reference

18 December 2017

issue

12

1 reference

18 December 2017

page(s)

2864-2872

1 reference

18 December 2017

cites work

Advances in IBD genetics

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Evaluation of the combined application of ethanol-fixed and formaldehyde-fixed neutrophil substrates for identifying atypical perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Pancreatic Autoantibodies in Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

The pancreatic zymogen granule membrane protein, GP2, binds Escherichia coli Type 1 fimbriae

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

The zymogen granule protein 2 (GP2) binds to scavenger receptor expressed on endothelial cells I (SREC-I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Glycoprotein 2 (GP2): grabbing the FimH bacteria into M cells for mucosal immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000564

10.1097/MIB.0000000000000564

21 January 2018

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017